Tweet
Published Online February 9 2012
< Science Express Index
Science DOI: 10.1126/science.1217697
REPORT
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Paige E. Cramer1, John R. Cirrito2, Daniel W. Wesson1,3 , C. Y. Daniel Lee1, J. Colleen Karlo1, Adriana E. Zinn1, Brad T. Casali1, Jessica L. Restivo2, Whitney D. Goebel2, Michael J. James4, Kurt R. Brunden4, Donald A. Wilson3, Gary E. Landreth1,*
ABSTRACT
Alzheimer's disease is associated with impaired clearance of β-amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE). ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator activated receptor (PPARγ) and liver X receptors (LXR) in coordination with retinoid X receptors (RXR). Oral administration of the RXR agonist, bexarotene, to a murine model of Alzheimer's disease resulted in enhanced clearance of soluble Aβ within hours in an apoE-dependent manner. Aβ plaque area was reduced >50% within just 72 hours.
Furthermore, bexarotene stimulated the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Thus, RXR activation stimulates physiological Aβ clearance mechanisms, resulting in the very rapid reversal of a broad range of Aβ-induced deficits.
< Science Express Index
Science DOI: 10.1126/science.1217697
REPORT
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Paige E. Cramer1, John R. Cirrito2, Daniel W. Wesson1,3 , C. Y. Daniel Lee1, J. Colleen Karlo1, Adriana E. Zinn1, Brad T. Casali1, Jessica L. Restivo2, Whitney D. Goebel2, Michael J. James4, Kurt R. Brunden4, Donald A. Wilson3, Gary E. Landreth1,*
ABSTRACT
Alzheimer's disease is associated with impaired clearance of β-amyloid from the brain, a process normally facilitated by apolipoprotein E (ApoE). ApoE expression is transcriptionally induced through the action of the nuclear receptors peroxisome proliferator activated receptor (PPARγ) and liver X receptors (LXR) in coordination with retinoid X receptors (RXR). Oral administration of the RXR agonist, bexarotene, to a murine model of Alzheimer's disease resulted in enhanced clearance of soluble Aβ within hours in an apoE-dependent manner. Aβ plaque area was reduced >50% within just 72 hours.
Furthermore, bexarotene stimulated the rapid reversal of cognitive, social, and olfactory deficits and improved neural circuit function. Thus, RXR activation stimulates physiological Aβ clearance mechanisms, resulting in the very rapid reversal of a broad range of Aβ-induced deficits.
